Compositions and methods for delivery of agents

Patent metadata

Field	Value
Publication number	US-10485885-B2
Application number	US-201816229509-A
Country	US
Kind code	B2
Filing date	Dec 21, 2018
Priority date	Dec 10, 2015
Publication date	Nov 26, 2019
Grant date	Nov 26, 2019

Abstract

This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.

First claim

What is claimed is:

1. A lipid nanoparticle (LNP) comprising a PEG-lipid, an ionizable amino lipid, a helper lipid, a structural lipid, and a biologically active agent;
wherein the PEG-lipid comprises a compound of Formula (V):

or a pharmaceutically acceptable salt thereof, wherein:
R 3 is OR O ; R O is hydrogen, optionally substituted alkyl or an oxygen protecting group; r is an integer between 1 and 100, inclusive; and R 5 is optionally substituted C 10-40 alkyl; and
wherein the ionizable amino lipid is a compound of Formula (XI):

or a pharmaceutically acceptable salt thereof, wherein:
l is selected from 1, 2, 3, 4, and 5;
M and M′ are independently selected from C(O)O, and OC(O);
M 1 is M′;
R 2 and R 3 are both C 1-14 alkyl, or C 2-14 alkenyl;
R 4 is (CH 2 ) n Q, in which Q is OH, and n is selected from 2, 3, or 4; and
R′ is a C 1 -C 18 linear alkyl.

2. The LNP of claim 1 , wherein R′ is C 9 alkyl.

3. The LNP of claim 1 , wherein n is 2.

4. The LNP of claim 1 , wherein the compound of Formula (XI) has the structure of compound 18:

or a pharmaceutically acceptable salt thereof.

5. The LNP of claim 1 , wherein the PEG-lipid is a compound of Formula (V-OH):

or a pharmaceutically acceptable salt thereof.

6. The LNP of claim 1 , wherein the compound of Formula (V) is Cmpd452:

7. The LNP of claim 6 , wherein the PEG lipid comprises a PEG molecule of an average molecular weight of 2,000 Da or less.

8. The LNP of claim 6 , wherein the PEG lipid is selected from HO-PEG2000-ester-C18, Methoxy-PEG2000-ester-C18, and Methoxy-PEG2000-ester-C20.

9. The LNP of claim 6 , wherein the PEG lipid is HO-PEG2000-ester-C18 (Cmpd403).

10. The LNP of claim 1 , wherein the helper lipid comprises:
at least one fatty acid chain of at least 8 carbons and at least one polar headgroup moiety, and wherein the helper lipid does not comprise a phosphatidyl choline (PC), and is a zwitterionic non-cationic helper lipid, a 1,2 distearoyl sn glycero 3 phosphocholine (DSPC) analog, oleic acid, an oleic acid analog, or a DSPC substitute; or wherein the helper lipid comprises DSPC.

11. The LNP of claim 1 , wherein the helper lipid is DSPC.

12. The LNP of claim 1 , wherein the structural lipid is a sterol.

13. The LNP of claim 1 , having a molar ratio of about 45-65% ionizable amino lipid, about 0.15-15% PEG-lipid, about 15-45% cholesterol and about 5-25% non-cationic helper lipid.

14. The LNP of claim 13 , wherein the PEG-lipid is present in the LNP in an amount of less than 0.5% (w/w).

15. The LNP of claim 1 , wherein the biologically active agent is a prophylactic agent, a therapeutic agent, immunomodulatory agent, or a diagnostic agent.

16. The LNP of claim 1 , wherein the biologically active agent is a nucleic acid molecule, protein, peptide, small organic compound, carbohydrate, or polysaccharide.

17. The LNP of claim 16 , wherein the biologically active agent is a nucleic acid molecule, and the nucleic acid molecule is RNA or DNA.

18. The LNP of claim 17 , wherein the RNA is mRNA, tRNA, rRNA, siRNA, or snRNA.

19. The LNP of claim 18 , wherein the RNA is mRNA.

20. The LNP of claim 19 , wherein the mRNA is chemically modified.

21. The LNP of claim 19 , wherein the mRNA comprises at least one miR binding site.

22. The LNP of claim 20 , wherein the mRNA encodes a protein.

23. The LNP of claim 17 , wherein the nucleic acid is DNA.

24. The LNP of claim 23 , wherein the DNA is a plasmid, cosmid, chromosome, chromatid, or recombinant DNA.

25. The LNP of claim 21 , wherein the miR binding site is selected from miR 122, miR 126, miR 155, and miR 142.3p.

26. A lipid nanoparticle (LNP) comprising HO-PEG2000-ester-C18 (Cmpd403); compound 18:

and a nucleic acid molecule.

27. The LNP of claim 26 , wherein the nucleic acid molecule is selected from the group consisting of: DNA, mRNA, tRNA, rRNA, siRNA, and snRNA.

28. The LNP of claim 27 , wherein the nucleic acid molecule is mRNA.

29. The LNP of claim 28 , wherein the mRNA comprises at least one miR binding site.

30. The LNP of claim 29 , wherein the miR binding site is selected from miR 122, miR 126, miR 155, and miR 142.3p.

Assignees

• Modernatx Inc

Inventors

• Besin Gilles
• Hoge Stephen
• Senn Joseph
• Benenato Kerry
• Sabnis Staci

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title